Amgen’s Amjevita is the first in a string of nine Humira biosimilars that are coming to market in 2023. All eyes are on these products as industry watchers ponder matters of exclusivity and market access to determine if biosimilars will be a successful venture in the US. In this two-part case study, our leaders will draw on lessons learned from the Humira biosimilars and engage in a predicative analysis of what this all means for other biosimilar launches